Skip to main content
SpringerLink
Log in

Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy

  • Laboratory Investigations
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

A condition similar to proliferative vitreoretinopathy (PVR) in man can be produced by injecting 25000 homologous dermal fibroblasts into rabbit eyes following gas compression of the vitreous. Daunorubicin (15 nmol) was effective in preventing retinal detachment in this model when injected simultaneously with the fibroblasts or in two doses (10 nmol followed by 5 nmol 4 h later) on the 3rd day after fibroblast injection. A single dose of 15 nmol on the 3rd day was not effective in preventing retinal detachment. These results suggest that daunorubicin may be clinically useful in preventing PVR when given by injection both at the time of vitrectomy as well as later, when protein exudation and pigment clumps in the vitreous cavity herald the onset of PVR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Algvere P, Kock E (1976) Experimental fibroplasia in the rabbit vitreous. Retinal detachment induced by autologous fibroblasts. Graefe's Arch Clin Exp Ophthalmol 199:215–222

    Google Scholar 

  2. Blumenkranz MS, Ophir A, Clafin AJ, Hajek A (1982) Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol 94:458–467

    Google Scholar 

  3. Case JL, Peyman GA, Barrada A, Hendricks R, Fiscella R, Hindi M (1985) Clearance of intravitreal [3H]-fluorouracil. Ophthalmic Surg 16:378–381

    Google Scholar 

  4. Chandler DB, Rozakis G, deJuan E, Machemer R (1985) The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 99:686–690

    Google Scholar 

  5. Chandler DB, Quanash FA, Hida T, Machemer R (1986) A refined experimental model for proliferative vitreoretinopathy. Graefe's Arch Clin Exp Ophthalmol 224:86–91

    Google Scholar 

  6. Chandler DB, Hida T, Sheta S, Proia AD, Machemer R (1987) Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefe's Arch Clin Exp Ophthalmol 225:259–265

    Google Scholar 

  7. Duarte-Karim M, Ruysschaert JM, Hildebrand J (1976) Affinity of Adriamycin to phospholipids — a possible explanation for cardiac mitochondrial lesions. Biochem Biophys Res Commun 71:658–663

    Google Scholar 

  8. Fastenberg DM, Diddie KR, Dorey K, Ryan SJ (1982) The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am J Ophthalmol 93:565–572

    Google Scholar 

  9. Gonvers N, Thresher R (1983) Temporary use of silicone oil in the treatment of proliferative vitreoretinopathy. An experimental study with a new animal model. Graefe's Arch Clin Exp Ophthalmol 221:46–53

    Google Scholar 

  10. Handa K, Sato S (1975) Generation of free radicals of quinone group containing anticancer chemicals in the NADPH-microsome system as evidenced by initiation of sulfate oxidation. Jpn J Cancer Res 66:43–47

    Google Scholar 

  11. Handa K, Sato S (1976) Stimulation of microsomal NADPH oxidation by quinone group containing anticancer chemicals. Jpn J Cancer Res 67:523–528

    Google Scholar 

  12. Hatchell DL, McAdoo T, Sheta S, King RT, Bartolome JV (1988) Quantification of cellular proliferation in experimental proliferative vitreoretinopathy. Arch Ophthalmol 106:669–672

    Google Scholar 

  13. Hida T, Chandler DB, Sheta SM (1987) Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye. Graefe's Arch Clin Exp Ophthalmol 225:303–307

    Google Scholar 

  14. Kirmani M, Santana M, Sorgente N, Wiedemann P, Ryan SJ (1983) Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina 3:269–272

    Google Scholar 

  15. Machemer R (1977) Massive periretinal proliferation. A logical approach to therapy. Trans Ophthalmol Soc UK 75:556–586

    Google Scholar 

  16. Machemer R (1978) Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol 62:737–747

    Google Scholar 

  17. Mikelens P, Levinson W (1978) Metal ion participation in binding of daunomycinol, daunomycin and Adriamycin to nucleic acids. Bioinorg Chem 9:441–452

    Google Scholar 

  18. Myers CE (1982) In: Chabner BA (ed) Pharmacologic principles of cancer treatment, Chap. 20. Saunders, Philadelphia, pp 416–434

    Google Scholar 

  19. Myers C, Simone C, Gianni R, Greene R, Klecker R, Hendickson M (1981) The role of doxorubicin-iron complex in superoxide production and membrane damage (abstr). Proc Am Assoc Cancer Res 22:128

    Google Scholar 

  20. Patel DJ, Cannel LL (1978) Anthracycline antitumor antibiotic nucleic acid interactions. Structural aspects of the daunomycin-DNA complex in solution. Eur J Biochem 90:247–254

    Google Scholar 

  21. Retina Society Terminology Meeting (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90:121–125

    Google Scholar 

  22. Santana M, Wiedemann P, Kirmani M, Minckler DS, Patterson R, Sorgente N, Ryan SJ (1984) Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefe's Arch Clin Exp Ophthalmol 221:210–213

    Google Scholar 

  23. Sato S, Iwaizumi M, Handa K, Tamura Y (1977) Electron spin resonance study on the mode of generation of free radicals of daunomycin, Adriamycin and carboquine in the NADPH microsomal system. Jpn J Cancer Res 68:603–608

    Google Scholar 

  24. Stern WH, Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK, O'Donnell JJ (1983) Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol 96:33–42

    Google Scholar 

  25. Sugita G, Tano Y, Machemer R, Abrams G, Clafin A, Fiorentino G (1980) Intravitreal autotransplantation of fibroblasts. Am J Ophthalmol 89:121–130

    Google Scholar 

  26. Tano Y, Chandler D, Machemer R (1980) Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 90:810–816

    Google Scholar 

  27. Thresher RJ, Ehrenberg M, Machemer R (1984) Gas-mediated vitreous compression: an experimental alternative to mechanized vitrectomy. Graefe's Arch Clin Exp Ophthalmol 221:192–198

    Google Scholar 

  28. Topping TM, Abrams GW, Machemer R (1979) Experimental double-perforating injury of the posterior segment in rabbit eyes. The natural history of intraocular proliferation. Arch Ophthalmol 97:735–742

    Google Scholar 

  29. Weller M, Heimann K, Wiedemann P (1987) Cytotoxic effects of daunomycin on retinal pigment epithelium in vitro. Graefe's Arch Clin Exp Ophthalmol 225:235–238

    Google Scholar 

  30. Wiedemann P, Kirmani M, Santana M, Sorgente N, Ryan SJ (1983) Control of experimental massive periretinal proliferation by daunomycin: dose-response relation. Graefe's Arch Clin Exp Ophthalmol 220:233–235

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University Eye Center and Durham Veterans Administration Medical Center, Durham, NC, USA

    Joseph A. Khawly, Peter Saloupis, Diane L. Hatchell & Robert Machemer

Authors
  1. Joseph A. Khawly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Saloupis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diane L. Hatchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert Machemer
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by NIH research grant EY02903, core grant EY05722, VA Medical Research Funds, Research to Prevent Blindness, Inc., and the Helena Rubenstein Foundation. D.L.H. is a Research to Prevent Blindness, Inc., Senior Scientific Investigator. The authors have no commercial or proprietary interest in the chemicals, drugs, or devices used in this study

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khawly, J.A., Saloupis, P., Hatchell, D.L. et al. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefe's Arch Clin Exp Ophthalmol 229, 464–467 (1991). https://doi.org/10.1007/BF00166311

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00166311

Keywords

Search

Navigation